Glimvea-M 2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glimvea-M 2 effective in patients inadequately controlled by diet and exercise alone. It is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose. The combination therapy minimizes the risk of hypoglycemia compared to sulfonylurea monotherapy and may also aid in weight management due to Metformin’s weight-neutral or weight-reducing effects. Glimvea-M 2 should be used cautiously in patients with renal or hepatic impairment and is contraindicated in conditions such as diabetic ketoacidosis, severe renal dysfunction, or acute metabolic acidosis. Regular monitoring of renal function, blood glucose, and HbA1c levels is recommended during treatment. Patients should be advised about potential side effects including gastrointestinal disturbances and hypoglycemia.